

Stefan O Schönland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4719228/publications.pdf>

Version: 2024-02-01

240
papers

8,694
citations

57631

44
h-index

54797

84
g-index

256
all docs

256
docs citations

256
times ranked

6858
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of AL proteins from 10 λ -AL amyloidosis patients by mass spectrometry extracted from abdominal fat and heart tissue. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2023, 30, 27-37.	1.4	4
2	Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2023, 30, 3-17.	1.4	22
3	A randomized phase 3 study of ixazomib+dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. <i>Leukemia</i> , 2022, 36, 225-235.	3.3	29
4	Response to extracorporeal photopheresis therapy of patients with steroid-refractory/resistant GvHD is associated with up-regulation of Th22 cells and Tfh cells. <i>Cytotherapy</i> , 2022, 24, 311-319.	0.3	7
5	Tissue biopsy for the diagnosis of amyloidosis: experience from some centres. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 8-13.	1.4	24
6	Dual-Echo Turbo Spin Echo and 12-Echo Multi Spin Echo Sequences as Equivalent Techniques for Obtaining T2-Relaxometry Data. <i>Investigative Radiology</i> , 2022, 57, 301-307.	3.5	5
7	Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	1
8	Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement. <i>PLoS ONE</i> , 2022, 17, e0264407.	1.1	10
9	Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allogeneic Stem Cell Transplantation. <i>Vaccines</i> , 2022, 10, 330.	2.1	9
10	Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation—study on behalf of CMWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 633-640.	1.3	4
11	Health-related quality of life in patients with λ light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone+daratumumab: Results from the ANDROMEDA study. <i>American Journal of Hematology</i> , 2022, 97, 719-730.	2.0	3
12	Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 817-823.	1.3	4
13	Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosis. <i>HemaSphere</i> , 2022, 6, e688.	1.2	1
14	Lysozyme amyloidosis—a report on a large German cohort and the characterisation of a novel amyloidogenic lysozyme gene variant. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 245-254.	1.4	5
15	Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3541.	1.0	4
16	Letemovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data. <i>Annals of Hematology</i> , 2021, 100, 2087-2093.	0.8	29
17	Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 210-217.	1.3	7
18	Solid state NMR assignments of a human λ -III immunoglobulin light chain amyloid fibril. <i>Biomolecular NMR Assignments</i> , 2021, 15, 9-16.	0.4	8

#	ARTICLE	IF	CITATIONS
19	Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 91-99.	1.4	8
20	Ruxolitinib is effective in the treatment of a patient with refractory T-ALL. <i>EJHaem</i> , 2021, 2, 139-142.	0.4	4
21	Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2021, 56, 529-531.	1.3	1
22	Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 1-2.	1.4	49
23	Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis. <i>Clinical Research in Cardiology</i> , 2021, 110, 579-590.	1.5	3
24	Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis. <i>Nature Communications</i> , 2021, 12, 875.	5.8	70
25	Prognostic impact of early versus late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT. <i>European Journal of Haematology</i> , 2021, 106, 708-715.	1.1	0
26	IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 686-693.	0.2	2
27	<scp>Daratumumab, lenalidomide, and dexamethasone</scp> in systemic <scp>light-chain</scp> amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21. <i>American Journal of Hematology</i> , 2021, 96, E253-E257.	2.0	13
28	Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party. <i>Bone Marrow Transplantation</i> , 2021, 56, 2367-2381.	1.3	1
29	Search for AL amyloidosis risk factors using Mendelian randomization. <i>Blood Advances</i> , 2021, 5, 2725-2731.	2.5	5
30	Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement. <i>European Journal of Haematology</i> , 2021, 107, 449-457.	1.1	13
31	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. <i>New England Journal of Medicine</i> , 2021, 385, 46-58.	13.9	268
32	Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up. <i>British Journal of Haematology</i> , 2021, 195, 230-243.	1.2	11
33	Submyeloablative total body irradiation-based conditioning and allogeneic stem cell transplantation in high-risk myeloma with early progression after upfront autologous transplantation. <i>British Journal of Haematology</i> , 2021, , .	1.2	1
34	Protease resistance of <i>ex vivo</i> amyloid fibrils implies the proteolytic selection of disease-associated fibril morphologies. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 243-251.	1.4	25
35	Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 999.e1-999.e10.	0.6	6
36	Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. <i>Blood Cancer Journal</i> , 2021, 11, 10.	2.8	53

#	ARTICLE	IF	CITATIONS
37	Role of mutations and post-translational modifications in systemic AL amyloidosis studied by cryo-EM. <i>Nature Communications</i> , 2021, 12, 6434.	5.8	36
38	Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival. <i>Blood</i> , 2021, 138, 2720-2720.	0.6	4
39	Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial. <i>Blood</i> , 2021, 138, 4771-4771.	0.6	0
40	Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients. <i>Blood</i> , 2021, 138, 153-153.	0.6	6
41	Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT. <i>Blood</i> , 2021, 138, 485-485.	0.6	0
42	Graded Renal Response Criteria for Light Chain (AL) Amyloidosis. <i>Blood</i> , 2021, 138, 2721-2721.	0.6	5
43	Th22 and Tfh Cell Elevation Is Associated with Clinical Response of Photopheresis Therapy in Patients with Steroid-Refractory/ Resistant Graft-Versus-Host Disease (GvHD). <i>Blood</i> , 2021, 138, 1810-1810.	0.6	0
44	Two-Year Evaluation of the German Clinical Amyloidosis Registry. <i>Blood</i> , 2021, 138, 3780-3780.	0.6	3
45	Treatment in AL Amyloidosis: Moving towards Individualized and Clone-Directed Therapy. <i>Hemato</i> , 2021, 2, 739-747.	0.2	1
46	A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis. <i>Clinical Research in Cardiology</i> , 2020, 109, 700-713.	1.5	13
47	Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance. <i>Leukemia</i> , 2020, 34, 1187-1191.	3.3	13
48	Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP. <i>European Journal of Haematology</i> , 2020, 104, 181-189.	1.1	7
49	Seeded fibrils of the germline variant of human λ -III immunoglobulin light chain FOR005 have a similar core as patient fibrils with reduced stability. <i>Journal of Biological Chemistry</i> , 2020, 295, 18474-18484.	1.6	15
50	Allogeneic Transplantation in Multiple Myeloma—Does It Still Have a Place?. <i>Journal of Clinical Medicine</i> , 2020, 9, 2180.	1.0	17
51	Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2020, 38, 3252-3260.	0.8	102
52	DUAL expectations in light chain amyloidosis. <i>EClinicalMedicine</i> , 2020, 24, 100461.	3.2	0
53	Stem Cell Mobilization and Autologous Transplant for Immunoglobulin Light-Chain Amyloidosis. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 1133-1144.	0.9	7
54	Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1559-1566.	2.0	6

#	ARTICLE	IF	CITATIONS
55	Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. <i>Blood</i> , 2020, 135, 1517-1530.	0.6	67
56	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. <i>British Journal of Haematology</i> , 2020, 190, 346-357.	1.2	17
57	Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 231-236.	1.4	20
58	Prognosis and Staging of AL Amyloidosis. <i>Acta Haematologica</i> , 2020, 143, 388-400.	0.7	34
59	CT features in amyloidosis of the respiratory system – Comprehensive analysis in a tertiary referral center cohort. <i>European Journal of Radiology</i> , 2020, 129, 109123.	1.2	9
60	Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression. <i>American Journal of Hematology</i> , 2020, 95, 1158-1169.	2.0	25
61	Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 799-807.	1.7	20
62	Treosulfan conditioning for allogeneic transplantation in multiple myeloma – improved overall survival in first line haematopoietic stem cell transplantation – a large retrospective study by the Chronic Malignancies Working Party of the EBMT. <i>British Journal of Haematology</i> , 2020, 189, e213-e217.	1.2	10
63	Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1810-1816.	1.3	31
64	Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda. <i>Blood</i> , 2020, 136, 48-50.	0.6	11
65	Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study. <i>Blood</i> , 2020, 136, 37-40.	0.6	5
66	First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network. <i>Blood</i> , 2020, 136, 50-51.	0.6	12
67	Ixazomib-dexamethasone (Ixa-Dex) vs physician’s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 8546-8546.	0.8	7
68	Fatal amyloid formation in a patient’s antibody light chain is caused by a single point mutation. <i>ELife</i> , 2020, 9, .	2.8	33
69	Daratumumab after Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Safety and Efficacy. a Retrospective Study from the CmwP EBMT. <i>Blood</i> , 2020, 136, 26-27.	0.6	0
70	Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type; A Study from the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2020, 136, 1-2.	0.6	0
71	Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis’ Survey. <i>Blood</i> , 2020, 136, 11-11.	0.6	0
72	Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients. <i>Blood</i> , 2020, 136, 33-34.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Gain 1q21 Is an Adverse Prognostic Factor in Patients with Relapsed/Refractory AL Amyloidosis Treated with Lenalidomide and Dexamethasone. <i>Blood</i> , 2020, 136, 17-18.	0.6	1
74	Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2019, 21, 53.	1.6	25
75	Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2134-2142.	2.0	52
76	Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2823-2834.	1.2	7
77	Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia. <i>Haematologica</i> , 2019, 104, 1451-1459.	1.7	29
78	AL amyloidosis with a localized B cell neoplasia. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 353-363.	1.4	15
79	New sequence variants in patients affected by amyloidosis show transthyretin instability by isoelectric focusing. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 85-93.	1.4	6
80	Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis. <i>Nature Communications</i> , 2019, 10, 1103.	5.8	120
81	Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. <i>Haematologica</i> , 2019, 104, 2274-2282.	1.7	27
82	Shaping of CD56 ^{bri} Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis. <i>Frontiers in Immunology</i> , 2019, 10, 547.	2.2	16
83	Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?. <i>Clinical Research in Cardiology</i> , 2019, 108, 1324-1330.	1.5	93
84	Tandem Autologous-Autologous Vs. Autologous-Allogeneic Transplantation for Newly Diagnosed Multiple Myeloma: Pooled Analysis of 1,338 Patients from Four Trials with Long-Term Follow up. <i>Blood</i> , 2019, 134, 259-259.	0.6	2
85	OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis. <i>Blood</i> , 2019, 134, 3163-3163.	0.6	4
86	Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL). <i>Blood</i> , 2019, 134, 139-139.	0.6	34
87	Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients. <i>Blood</i> , 2019, 134, 3166-3166.	0.6	27
88	Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017. <i>Blood</i> , 2019, 134, 4575-4575.	0.6	3
89	Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT. <i>Blood</i> , 2019, 134, 324-324.	0.6	2
90	Systemic Light Chain Amyloidosis. , 2019, , 609-614.		1

#	ARTICLE	IF	CITATIONS
91	High-Throughput Immunofluorescence and Electron Tomography to Characterize Centrosomal Aberrations in Plasma Cell Neoplasia. <i>Blood</i> , 2019, 134, 3077-3077.	0.6	0
92	A Semi-Automated Knime-Based Workflow for High Throughput Quantification and Analysis of Centrosome Aberrations. <i>Blood</i> , 2019, 134, 3379-3379.	0.6	0
93	Maintaining the Cellular Anti-Viral and Anti-Leukemic Activities in GvHD Patients Undergoing Extracorporeal Photophoresis Therapy. <i>Blood</i> , 2019, 134, 3287-3287.	0.6	0
94	Safety and Efficacy of Autologous Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients - the Diadem Study from the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2019, 134, 4574-4574.	0.6	1
95	Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 930-936.	2.0	11
96	Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1372-1378.	2.0	20
97	Obesity is a significant susceptibility factor for idiopathic AA amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 37-45.	1.4	24
98	Melphalan 140 mg/m ² or 200 mg/m ² for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. <i>Haematologica</i> , 2018, 103, 514-521.	1.7	70
99	Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 611-618.	0.3	66
100	Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 767-776.	0.7	13
101	The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience. <i>Annals of Hematology</i> , 2018, 97, 1241-1250.	0.8	31
102	Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice. <i>Hematological Oncology</i> , 2018, 36, 210-216.	0.8	14
103	First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival. <i>Blood</i> , 2018, 131, 368-371.	0.6	30
104	Diagnostic work up of an adult female patient with systemic AA amyloidosis revealing the cause of infantile mental retardation. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 68-69.	1.4	0
105	Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation. <i>Haematologica</i> , 2018, 103, 336-343.	1.7	18
106	Optimizing Outcomes after Heart Transplantation in Patients with Cardiac Amyloidosis - A Single Center Analysis of 48 Patients in 2 Eras. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 592.	0.3	0
107	Deferred autologous stem cell transplantation in systemic AL amyloidosis. <i>Blood Cancer Journal</i> , 2018, 8, 101.	2.8	28
108	Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects. <i>Frontiers in Immunology</i> , 2018, 9, 2207.	2.2	21

#	ARTICLE	IF	CITATIONS
109	Systemic immunoglobulin light chain amyloidosis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 38.	18.1	350
110	Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. <i>Blood Advances</i> , 2018, 2, 2607-2618.	2.5	33
111	<scp>CD</scp>7 is expressed on a subset of normal <scp>CD</scp>34â€positive myeloid precursors. <i>European Journal of Haematology</i> , 2018, 101, 318-325.	1.1	6
112	MR neurography biomarkers to characterize peripheral neuropathy in AL amyloidosis. <i>Neurology</i> , 2018, 91, e625-e634.	1.5	24
113	Local vs. systemic pulmonary amyloidosisâ€™ impact on diagnostics and clinical management. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 627-637.	1.4	31
114	Treatment of AL amyloidosis with bendamustine: a study of 122 patients. <i>Blood</i> , 2018, 132, 1988-1991.	0.6	30
115	Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e493-e499.	0.2	20
116	CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myelomaâ€™ Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance. <i>Frontiers in Immunology</i> , 2018, 9, 1676.	2.2	32
117	AL Amyloidosis â€™ Pathogenesis and Prognosis Are Determined By the Amyloidogenic Potential of the Light Chain and the Molecular Characteristics of Malignant Plasma Cells. <i>Blood</i> , 2018, 132, 187-187.	0.6	5
118	Incidence of Acute Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation over Time: A Study from the Transplant Complications and Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2018, 132, 2120-2120.	0.6	11
119	Results of Autologous and Allogeneic Transplantation in Patients with Primary Plasma Cell Leukemia: A Large Retrospective Analysis of the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2018, 132, 3425-3425.	0.6	3
120	Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: Safety run-in results of andromeda.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8011-8011.	0.8	5
121	Pomalidomide and Dexamethasone Grant Rapid Hematologic Responses in Patients with Relapsed and Refractory AL Amyloidois: A European Retrospective Series of 150 Patients. <i>Blood</i> , 2018, 132, 3264-3264.	0.6	0
122	No Inhibition of Anti-Viral and Anti-Leukemia Effects By Extracorporeal Photopheresis Therapy. <i>Blood</i> , 2018, 132, 3399-3399.	0.6	1
123	Impact of Upfront Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma with Del(17) and t(4;14): A Report from the EBMT Chronic Malignancies Working Party. <i>Blood</i> , 2018, 132, 2143-2143.	0.6	2
124	Potential therapeutic targets in plasma cell disorders: A flow cytometry study. <i>Cytometry Part B - Clinical Cytometry</i> , 2017, 92, 145-152.	0.7	13
125	Mutational landscape reflects the biological continuum of plasma cell dyscrasias. <i>Blood Cancer Journal</i> , 2017, 7, e537-e537.	2.8	32
126	Amyloid in bone marrow smears in systemic light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 52-59.	1.4	18

#	ARTICLE	IF	CITATIONS
127	Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 56-57.	1.4	9
128	Myocardial contraction fraction derived from cardiovascular magnetic resonance cine images—reference values and performance in patients with heart failure and left ventricular hypertrophy. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 1414-1422.	0.5	32
129	Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up. <i>Haematologica</i> , 2017, 102, 1424-1431.	1.7	39
130	Common Fibril Structures Imply Systemically Conserved Protein Misfolding Pathways In Vivo. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 7510-7514.	7.2	59
131	Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with <scp>CLL</scp>: a retrospective analysis from the European Society for Blood and Marrow Transplantation (<scp>EBMT</scp>). <i>British Journal of Haematology</i> , 2017, 178, 521-533.	1.2	26
132	AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. <i>Blood</i> , 2017, 130, 632-642.	0.6	104
133	A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. <i>Blood</i> , 2017, 130, 597-605.	0.6	108
134	Common Fibril Structures Imply Systemically Conserved Protein Misfolding Pathways In Vivo. <i>Angewandte Chemie</i> , 2017, 129, 7618-7622.	1.6	10
135	Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis. <i>Haematologica</i> , 2017, 102, 1281-1290.	1.7	15
136	Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1193-1202.	2.0	14
137	Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma. <i>Leukemia</i> , 2017, 31, 1735-1742.	3.3	32
138	Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate. <i>Journal of Biological Chemistry</i> , 2017, 292, 2328-2344.	1.6	37
139	Comparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1870-1878.	2.0	9
140	Flow in a fibril-forming disease. <i>Blood</i> , 2017, 129, 7-8.	0.6	2
141	Sural nerve injury in familial amyloid polyneuropathy. <i>Neurology</i> , 2017, 89, 475-484.	1.5	48
142	Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts. <i>Haematologica</i> , 2017, 102, e411-e414.	1.7	7
143	Incremental value of cardiac magnetic resonance for the evaluation of cardiac tumors in adults: experience of a high volume tertiary cardiology centre. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 879-888.	0.7	22
144	Regional differences in prognostic value of cardiac valve plane displacement in systemic light-chain amyloidosis. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2017, 19, 87.	1.6	12

#	ARTICLE	IF	CITATIONS
145	Polymorphism of Amyloid Fibrils In Vivo. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 4822-4825.	7.2	109
146	Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. <i>Blood</i> , 2016, 128, 594-602.	0.6	67
147	Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis. <i>Cancer Medicine</i> , 2016, 5, 1464-1472.	1.3	25
148	Anterior Aortic Plane Systolic Excursion: A Novel Indicator of Transplant-Free Survival in Systemic Light-Chain Amyloidosis. <i>Journal of the American Society of Echocardiography</i> , 2016, 29, 1188-1196.	1.2	11
149	First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. <i>Journal of Clinical Oncology</i> , 2016, 34, 1097-1103.	0.8	176
150	Amyloid in biopsies of the gastrointestinal tract—a retrospective observational study on 542 patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 569-577.	1.4	93
151	Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT Tj ETQq1 1 0.784314 rgBT /Ove	0.6	7
152	Comparison of Haematopoietic Stem Cell Transplantation Approaches in Primary Plasma Cell Leukaemia. <i>Blood</i> , 2016, 128, 2293-2293.	0.6	2
153	Allogeneic Hematopoietic Stem Cell Transplantation in Hemophagocytic Lymphohistiocytosis (HLH) in Adults: A Retrospective Study of the Chronic Malignancies and Inborn Errors Working Parties (CMWP) Tj ETQq1 1 0.784314 rgBT /Ove	0.6	7
154	Comparison of Allogeneic Stem Cell Transplantation for Transformed Acute Myeloid Leukemia Derived from MDS, CMML or MPN. a Report of the Chronic Malignancies Working Party of EBMT. <i>Blood</i> , 2016, 128, 3499-3499.	0.6	2
155	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. <i>Blood</i> , 2016, 128, 646-646.	0.6	37
156	Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2016, 128, 993-993.	0.6	9
157	The PRONTO amyloidosis study: A randomized, double-blind, placebo-controlled, global, phase 2b study of NEOD001 in previously treated subjects with light chain amyloidosis and persistent cardiac dysfunction.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS8073-TPS8073.	0.8	2
158	Efficacy and Tolerability of the Histone-Deacetylase Inhibitor Panobinostat in Clinical Practice: a Single Center Experience. <i>Blood</i> , 2016, 128, 5686-5686.	0.6	0
159	Amyloidogenicity of Immunoglobulin Light Chains. <i>Biophysical Journal</i> , 2015, 108, 386a.	0.2	0
160	Prognostic significance of semiautomatic quantification of left ventricular long axis shortening in systemic light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2015, 22, 45-53.	1.4	15
161	Reply to R. Warsame et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 3976-3977.	0.8	2
162	Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMA2000 prospective trial. <i>Bone Marrow Transplantation</i> , 2015, 50, 505-510.	1.3	16

#	ARTICLE	IF	CITATIONS
163	Risk factors for AA amyloidosis in Germany. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2015, 22, 1-7.	1.4	24
164	Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse. <i>Bone Marrow Transplantation</i> , 2015, 50, 1279-1285.	1.3	33
165	Association of Antigen-Specific T-cell Responses with Antigen Expression and Immunoparalysis in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 1712-1721.	3.2	14
166	Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens. <i>Journal of Clinical Oncology</i> , 2015, 33, 1371-1378.	0.8	185
167	In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography. <i>Brain</i> , 2015, 138, 549-562.	3.7	112
168	Clinical and Cytogenetic Characterization of Light Chain Amyloidosis Patients with a Low Amyloidogenic Free Light Chain Count at First Diagnosis. <i>Blood</i> , 2015, 126, 1790-1790.	0.6	2
169	The EBMT Score Predicts Transplant Related Mortality and Overall Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 3223-3223.	0.6	2
170	The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis. <i>Blood</i> , 2015, 126, 3049-3049.	0.6	0
171	Immunoglobulin light-chain amyloidosis shares genetic susceptibility with multiple myeloma. <i>Leukemia</i> , 2014, 28, 2254-2256.	3.3	12
172	The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison. <i>Annals of Oncology</i> , 2014, 25, 200-206.	0.6	35
173	Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 202-210.	1.4	15
174	Evaluation of the clinical use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for risk stratification in patients with light-chain amyloidosis. <i>International Journal of Cardiology</i> , 2014, 176, 1113-1115.	0.8	6
175	Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 9-17.	1.4	84
176	A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. <i>Blood</i> , 2014, 124, 2325-2332.	0.6	366
177	Detection and Characterization of Plasma Cell and B Cell Clones in Patients with Systemic Light Chain Amyloidosis Using Flow Cytometry. <i>Blood</i> , 2014, 124, 2068-2068.	0.6	3
178	Long-Term Follow-up Data Support the Curative Potential of Allogeneic Hematopoietic Cell Transplantation in Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis from the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2014, 124, 2561-2561.	0.6	3
179	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. <i>Blood</i> , 2014, 124, 35-35.	0.6	11
180	Low Pre-Transplant Levels of 25-Hydroxyvitamin D3 Predict Relapse and Survival in Male but Not in Female Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 1181-1181.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. <i>International Journal of Cardiology</i> , 2013, 164, 179-184.	0.8	37
182	Doxycycline in ATTRY69H (p.ATTRY89H) amyloidosis with predominant leptomeningeal manifestation. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2013, 20, 279-280.	1.4	4
183	Postallograft lenalidomide induces strong NK cell-mediated antitumor activity and risk for T cell-mediated GVHD: Results from a phase I/II dose-finding study. <i>Experimental Hematology</i> , 2013, 41, 134-142.e3.	0.2	83
184	Familial Mediterranean fever in Germany: clinical presentation and amyloidosis risk. <i>Scandinavian Journal of Rheumatology</i> , 2013, 42, 52-58.	0.6	23
185	Cerebral amyloid angiopathy – an underdiagnosed entity in younger adults with lobar intracerebral hemorrhage?. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2013, 20, 45-47.	1.4	22
186	Reply to S. Girnius et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 2750-2751.	0.8	1
187	Modified body mass index and time interval between diagnosis and operation affect survival after liver transplantation for hereditary amyloidosis: a single-center analysis. <i>Clinical Transplantation</i> , 2013, 27, 40-48.	0.8	17
188	Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. <i>Blood</i> , 2013, 121, 5055-5063.	0.6	171
189	A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. <i>Blood</i> , 2013, 121, 3420-3427.	0.6	385
190	Reduced Intensity Allogeneic Stem Cell Transplant In Patients With Multiple Myeloma: A Comparison Of Planned Autologous-Reduced Intensity Allogeneic Stem Cell Transplant (Auto-Allo) and Reduced Intensity Allogeneic Stem Cell Transplant (RIC) As Upfront Transplant In Patients With Multiple Myeloma, An EBMT Analysis. <i>Blood</i> , 2013, 122, 920-920.	0.6	2
191	Lenalidomide/Melphalan / Dexamethasone Chemotherapy In 50 Patients With Newly Diagnosed Amyloid Light Chain Amyloidosis: First Results Of a Prospective Single Center Phase 2 Study (Leomex). <i>Blood</i> , 2013, 122, 1993-1993.	0.6	1
192	Center Experience and Calendar Year Of Transplantation Strongly Influence Short Term Survival After Autologous Peripheral Blood Transplantation In 1315 Patients With Light Chain Amyloidosis: An EBMT Analysis. <i>Blood</i> , 2013, 122, 417-417.	0.6	1
193	Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2012, 47, 895-905.	1.3	37
194	Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. <i>Blood</i> , 2012, 119, 488-493.	0.6	200
195	New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes. <i>Journal of Clinical Oncology</i> , 2012, 30, 4541-4549.	0.8	735
196	Longitudinal Left Ventricular Function for Prediction of Survival in Systemic Light-Chain Amyloidosis. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1067-1076.	1.2	253
197	CD4+CD25highCD127low Regulatory T Cells in Peripheral Blood Are Not an Independent Factor for Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation. <i>Scientific World Journal</i> , 2012, 2012, 1-10.	0.8	7
198	Therapy of AL amyloidosis – work-up and treatment at our centre. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 18-22.	0.3	1

#	ARTICLE	IF	CITATIONS
199	Rapid assessment of longitudinal systolic left ventricular function using speckle tracking of the mitral annulus. <i>Clinical Research in Cardiology</i> , 2012, 101, 273-280.	1.5	43
200	Treatment of AL Amyloidosis with Bendamustine. <i>Blood</i> , 2012, 120, 4057-4057.	0.6	5
201	MLN9708, a Novel, Investigational Oral Proteasome Inhibitor, in Patients with Relapsed or Refractory Light-Chain Amyloidosis (AL): Results of a Phase 1 Study. <i>Blood</i> , 2012, 120, 731-731.	0.6	12
202	Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14). <i>Blood</i> , 2011, 117, 3809-3815.	0.6	60
203	European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease. <i>Blood</i> , 2011, 118, 995-995.	0.6	5
204	Gain of 1q21 Is a Cytogenetic Independent Risk Factor in Light Chain Amyloidosis Patients Treated with Melphalan / Dexamethasone As First-Line Therapy,. <i>Blood</i> , 2011, 118, 3946-3946.	0.6	0
205	Comparison of Autologous and Allogeneic Transplantation As Therapy of First Relapse in Patients with Multiple Myeloma - Long-Term Follow up Analysis,. <i>Blood</i> , 2011, 118, 4124-4124.	0.6	0
206	Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. <i>Blood</i> , 2010, 116, 522-528.	0.6	84
207	Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. <i>Blood</i> , 2010, 116, 2455-2461.	0.6	109
208	Amyloid in endomyocardial biopsies. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 456, 523-532.	1.4	50
209	Validation of the Criteria of Response to Treatment In AL Amyloidosis,. <i>Blood</i> , 2010, 116, 1364-1364.	0.6	19
210	Efficacy and Toxicity of Dose-Reduced Bortezomib/Dexamethasone Chemotherapy In Patients with High Risk Cardiac Light Chain Amyloidosis (Mayo Clinic stage III). <i>Blood</i> , 2010, 116, 1960-1960.	0.6	1
211	Dose Finding Study of Lenalidomide as Maintenance Therapy In Multiple Myeloma After Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2010, 116, 2376-2376.	0.6	2
212	Donor lymphocyte infusions in amyloid light chain amyloidosis: induction of a "graft-versus-plasma cell-dyscrasia effect". <i>Haematologica</i> , 2009, 94, 439-441.	1.7	5
213	Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis. <i>European Journal of Heart Failure</i> , 2009, 11, 1014-1020.	2.9	45
214	Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. <i>Human Mutation</i> , 2009, 30, 1567-1573.	1.1	107
215	Hereditary Apolipoprotein AI-Associated Amyloidosis in Surgical Pathology Specimens. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 257-262.	1.2	116
216	Prevalence of Germline Mutations in the TTR Gene in a Consecutive Series of Surgical Pathology Specimens With ATTR Amyloid. <i>American Journal of Surgical Pathology</i> , 2009, 33, 58-65.	2.1	39

#	ARTICLE	IF	CITATIONS
217	Prospective Phase II Study Using Dexamethasone Induction Therapy and High-Dose Melphalan Chemotherapy Followed by Autologous Stem Cell Transplantation in 30 Patients with Systemic AL Amyloidosis.. <i>Blood</i> , 2009, 114, 3401-3401.	0.6	1
218	Hyperdiploidy Is Rare in Patients with AL Amyloidosis – Identification of Major Cytogenetic Groups in Early Monoclonal Plasma Cell Disorders.. <i>Blood</i> , 2009, 114, 2823-2823.	0.6	1
219	Three German fibrinogen A α -chain amyloidosis patients with the p.Glu526Val mutation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 453, 25-31.	1.4	21
220	Sjögren's syndrome and localized nodular cutaneous amyloidosis: Coincidence or a distinct clinical entity?. <i>Arthritis and Rheumatism</i> , 2008, 58, 1992-1999.	6.7	61
221	Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. <i>Bone Marrow Transplantation</i> , 2008, 41, 779-784.	1.3	44
222	Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. <i>Heart Rhythm</i> , 2008, 5, 235-240.	0.3	214
223	Respiratory muscle weakness and inefficient ventilation in heart failure due to light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2008, 15, 129-136.	1.4	1
224	Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. <i>Haematologica</i> , 2008, 93, 459-462.	1.7	62
225	Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. <i>Blood</i> , 2008, 111, 4700-4705.	0.6	103
226	Bone involvement in patients with systemic AL amyloidosis mimics lytic myeloma bone disease. <i>Haematologica</i> , 2008, 93, 955-956.	1.7	14
227	Defective Telomerase in Familial Myelodysplasia and Leukemia. <i>Blood</i> , 2008, 112, 849-849.	0.6	0
228	Non-invasive predictors of survival in cardiac amyloidosis. <i>European Journal of Heart Failure</i> , 2007, 9, 617-624.	2.9	109
229	Rapid Progression of Left Ventricular Wall Thickness Predicts Mortality in Cardiac Light-chain Amyloidosis. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 1313-1319.	0.3	52
230	Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. <i>Haematologica</i> , 2007, 92, 1513-1518.	1.7	34
231	Evaluation of the Cytogenetic Aberration Pattern in AL Amyloidosis Compared to Monoclonal Gammopathies Not Requiring Treatment: Translocation t(11;14) Is More Frequent in AL Amyloidosis.. <i>Blood</i> , 2007, 110, 2500-2500.	0.6	1
232	Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2006, 107, 2578-2584.	0.6	62
233	Polychemotherapy in Combination with Thalidomide Followed by Autologous or Allogeneic Transplantation for Rescue after Autograft or Induction Therapy Failure in Patients with Multiple Myeloma.. <i>Blood</i> , 2006, 108, 3018-3018.	0.6	0
234	Indications for Liver Transplantation in Patients with Amyloidosis: A Single-Center Experience with 11 Cases. <i>Transplantation</i> , 2005, 80, S156-S159.	0.5	16

#	ARTICLE	IF	CITATIONS
235	Indications for High-Dose Chemotherapy with Autologous Stem Cell Support in Patients with Systemic Amyloid Light Chain Amyloidosis. <i>Transplantation</i> , 2005, 80, S160-S163.	0.5	18
236	Risk Stratification in Cardiac Amyloidosis: Novel Approaches. <i>Transplantation</i> , 2005, 80, S151-S155.	0.5	23
237	High-Dose Melphalan Chemotherapy with Autologous Stem Cell Transplantation in Patients with AL Amyloidosis: No Increased Mortality Using Induction and Mobilization Chemotherapy.. <i>Blood</i> , 2005, 106, 5505-5505.	0.6	0
238	High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. <i>British Journal of Haematology</i> , 2004, 127, 543-551.	1.2	62
239	Premature telomeric loss in rheumatoid arthritis is genetically determined and involves both myeloid and lymphoid cell lineages. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 13471-13476.	3.3	185
240	Homeostatic control of T-cell generation in neonates. <i>Blood</i> , 2003, 102, 1428-1434.	0.6	158